IMIDomics expands long-standing partnership with Bristol Myers Squibb to advance immune-mediated inflammatory disease treatment research and development

by CataloniaBio

This expanded partnership extends the existing relationship between the two companies, advancing their shared commitment to accelerate research and development aimed at treating IMID patients.

Read more

IMIDomics, a Vall d'Hebron spin-off, raises $16.5 million to develop new drugs against immunomediated inflammatory diseases

by Vall d’Hebron

This investment will allow IMIDomics to accelerate the identification of new therapeutic targets and the development of new drugs for immune-mediated inflammatory diseases (IMID), like rheumatoid arth...

Read more
Subscribe to Directory
Write an Article

Recent News

Exposure to Heat and Cold During Pregnan...

The research team observed changes in head circumf...

Using mobile RNAs to improve Nitrogen a...

AtCDF3 gene induced greater production of sugars a...

El diagnóstico genético neonatal mejor...

Un estudio con datos de los últimos 35 años, ind...

Highlight

Eosinófilos. ¿Qué significa tener val...

by Labo'Life

​En nuestro post hablamos sobre este interesante tipo de célula del...

A dietary supplement has beneficial effe...

by Institute for Advanced Chemistry of Catalonia (IQAC-CSIC)

Research led by IIBB-CSIC and CIBEREHD scientists identifies S-adenosy...

Photos Stream